Pharmaceuticals

A new partnership will embed real-world cell therapy manufacturing into NJIT's graduate program, aiming to fill a critical skills gap in the biotech industry.

A key recommendation for the drug BIMZELX could soon give Quebec patients a powerful new weapon against the debilitating skin disease hidradenitis suppurativa.

A novel three-in-one antibody from CStone shows a 90% response rate in lung cancer and potent activity in 'cold tumors,' heralding a new era for immunotherapy.

PetaSight's acquisition of Babbage Insight aims to fix a broken system with an 'intelligent OS', tackling the 38% data discard rate in life sciences PMR.

A new lithium formula boosts brain delivery in a key trial, offering hope for safer, more effective treatments for Alzheimer's, bipolar disorder, and more.

A new RNA drug shows promise by reducing harmful belly fat while preserving muscle, but modest overall weight loss in early trials spooks investors.

A new partnership between Boehringer Ingelheim and the CT Science Center seeks to build a talent pipeline for the state's booming biopharma industry.

The successful launch of rosacea treatment Emrosi™ generated $14.7M, driving Journey Medical's revenue to $61.9M and signaling a major strategic win.

Weave Bio forms a star-studded advisory board with leaders from Gilead and Takeda to navigate the high-stakes world of AI in drug development.

The FDA has clarified its rules for desiccated thyroid extract (DTE), providing relief for patients and a new path forward for manufacturers like Acella.

A potential first-ever treatment for a severe rare skin disease gets a major boost from the FDA, accelerating its path to patients and exciting investors.

SciTech's ST-001 overcomes a decades-old barrier for fenretinide, showing promising results for Cutaneous T-Cell Lymphoma patients in early trials.

With CE Mark approval, Countable Labs brings single-molecule counting PCR to Europe, promising unprecedented precision for gene therapy and diagnostics.

Following a 40-year career shaping biotech finance, Jessica Chutter's move to PTC's board signals major strategic ambitions for the rare disease firm.

Biolojic Design's adaptive AI drug for asthma and eczema hits a key milestone with Teva, heralding a new era for personalized autoimmune treatment.

From the heart of Arabia, AlUla Peregrina brings a patented active to the global stage, promising scientifically-backed, ethical longevity beauty.

Venture capital leaders and national security experts caution that drug pricing controls and regulatory hurdles could cede America's biomedical edge to rivals.

Sequoia Group launches 'Pages,' a collaborative workspace, and its 2026 report to help firms navigate rising costs, AI talent wars, and compensation.

With a top expert at the helm, AltaThera aims to expand its heart rhythm drug for kids, balancing life-saving potential with critical safety warnings.

US brands hit a record $6.44T value, led by tech titans. But as corporate power grows, America's global reputation is in a steep, historic decline.